Cargando…

GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients

Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score,...

Descripción completa

Detalles Bibliográficos
Autores principales: Schotten, Clemens, Ostertag, Bastian, Sowa, Jan-Peter, Manka, Paul, Bechmann, Lars P., Hilgard, Gudrun, Marquardt, Claudio, Wichert, Marc, Toyoda, Hidenori, Lange, Christian M., Canbay, Ali, Johnson, Philip, Wedemeyer, Heiner, Best, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401792/
https://www.ncbi.nlm.nih.gov/pubmed/34451832
http://dx.doi.org/10.3390/ph14080735
_version_ 1783745635143385088
author Schotten, Clemens
Ostertag, Bastian
Sowa, Jan-Peter
Manka, Paul
Bechmann, Lars P.
Hilgard, Gudrun
Marquardt, Claudio
Wichert, Marc
Toyoda, Hidenori
Lange, Christian M.
Canbay, Ali
Johnson, Philip
Wedemeyer, Heiner
Best, Jan
author_facet Schotten, Clemens
Ostertag, Bastian
Sowa, Jan-Peter
Manka, Paul
Bechmann, Lars P.
Hilgard, Gudrun
Marquardt, Claudio
Wichert, Marc
Toyoda, Hidenori
Lange, Christian M.
Canbay, Ali
Johnson, Philip
Wedemeyer, Heiner
Best, Jan
author_sort Schotten, Clemens
collection PubMed
description Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score, which incorporates gender, age, and serum levels of AFP, AFP isoform L3 (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), can improve early-stage HCC detection in a Caucasian HBV/HCV cohort. In a retrospective German single-center study, 182 patients with HBV, 223 with HCV and 168 with other etiology (OE) of chronic liver disease (CLD) were enrolled. HCC was confirmed in 52 HBV, 84 HCV and 60 OE CLD patients. The diagnostic performance of the single biomarkers in HCC detection was compared to the GALAD model. At initial diagnosis, most patients were at (very) early BCLC 0 (n = 14/7%) or A (n = 56/29%) or intermediate stage BCLC B (n = 93/47%) HCC in all three subgroups. In the BCLC 0/A cohort, GALAD exhibited an AUC of 0.94 discriminating HCC from non-HCC, surpassing AFP (AUC 0.86), AFP-L3 (AUC 0.83) and DCP (AUC 0.83). In the HBV population, GALAD achieved an AUC of 0.96, in HCV an AUC of 0.98 and in OE an AUC of 0.99, clearly superior to the biomarkers alone. Furthermore, in HCV patients GALAD showed a significantly higher specificity (89%) versus AFP (64%) alone. In chronic viral hepatitis, the GALAD model showed superior performance in detection of early-stage HCC, while exhibiting higher specificity in HCV patients compared to AFP alone. We conclude that the GALAD score shows potential for HCC surveillance in Caucasian HBV/HCV patients.
format Online
Article
Text
id pubmed-8401792
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84017922021-08-29 GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients Schotten, Clemens Ostertag, Bastian Sowa, Jan-Peter Manka, Paul Bechmann, Lars P. Hilgard, Gudrun Marquardt, Claudio Wichert, Marc Toyoda, Hidenori Lange, Christian M. Canbay, Ali Johnson, Philip Wedemeyer, Heiner Best, Jan Pharmaceuticals (Basel) Article Despite vaccination programs and direct antiviral treatments, the incidence of virus-related hepatocellular carcinoma (HCC) remains high, while ultrasound-based detection rates for early-stage HCC is continuously low. To address this insufficiency, we set out to characterize whether the GALAD score, which incorporates gender, age, and serum levels of AFP, AFP isoform L3 (AFP-L3), and des-gamma-carboxy-prothrombin (DCP), can improve early-stage HCC detection in a Caucasian HBV/HCV cohort. In a retrospective German single-center study, 182 patients with HBV, 223 with HCV and 168 with other etiology (OE) of chronic liver disease (CLD) were enrolled. HCC was confirmed in 52 HBV, 84 HCV and 60 OE CLD patients. The diagnostic performance of the single biomarkers in HCC detection was compared to the GALAD model. At initial diagnosis, most patients were at (very) early BCLC 0 (n = 14/7%) or A (n = 56/29%) or intermediate stage BCLC B (n = 93/47%) HCC in all three subgroups. In the BCLC 0/A cohort, GALAD exhibited an AUC of 0.94 discriminating HCC from non-HCC, surpassing AFP (AUC 0.86), AFP-L3 (AUC 0.83) and DCP (AUC 0.83). In the HBV population, GALAD achieved an AUC of 0.96, in HCV an AUC of 0.98 and in OE an AUC of 0.99, clearly superior to the biomarkers alone. Furthermore, in HCV patients GALAD showed a significantly higher specificity (89%) versus AFP (64%) alone. In chronic viral hepatitis, the GALAD model showed superior performance in detection of early-stage HCC, while exhibiting higher specificity in HCV patients compared to AFP alone. We conclude that the GALAD score shows potential for HCC surveillance in Caucasian HBV/HCV patients. MDPI 2021-07-27 /pmc/articles/PMC8401792/ /pubmed/34451832 http://dx.doi.org/10.3390/ph14080735 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schotten, Clemens
Ostertag, Bastian
Sowa, Jan-Peter
Manka, Paul
Bechmann, Lars P.
Hilgard, Gudrun
Marquardt, Claudio
Wichert, Marc
Toyoda, Hidenori
Lange, Christian M.
Canbay, Ali
Johnson, Philip
Wedemeyer, Heiner
Best, Jan
GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title_full GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title_fullStr GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title_full_unstemmed GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title_short GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients
title_sort galad score detects early-stage hepatocellular carcinoma in a european cohort of chronic hepatitis b and c patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401792/
https://www.ncbi.nlm.nih.gov/pubmed/34451832
http://dx.doi.org/10.3390/ph14080735
work_keys_str_mv AT schottenclemens galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT ostertagbastian galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT sowajanpeter galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT mankapaul galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT bechmannlarsp galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT hilgardgudrun galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT marquardtclaudio galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT wichertmarc galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT toyodahidenori galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT langechristianm galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT canbayali galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT johnsonphilip galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT wedemeyerheiner galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients
AT bestjan galadscoredetectsearlystagehepatocellularcarcinomainaeuropeancohortofchronichepatitisbandcpatients